A share of ADC Therapeutics SA (NYSE:ADCT) closed at $2.05 per share on Monday, up from $1.95 day before. While ADC Therapeutics SA has overperformed by 5.13%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ADCT fell by -86.04%, with highs and lows ranging from $16.04 to $1.85, whereas the simple moving average fell by -59.89% in the last 200 days.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
On December 06, 2022, CapitalOne started tracking ADC Therapeutics SA (NYSE: ADCT) recommending Overweight. A report published by BofA Securities on November 09, 2022, Downgraded its rating to ‘Neutral’ for ADCT. JP Morgan also rated ADCT shares as ‘Overweight’, setting a target price of $5 on the company’s shares in an initiating report dated September 21, 2022. Morgan Stanley September 09, 2022d the rating to Equal-Weight on September 09, 2022, and set its price target from $17 to $11. Wolfe Research initiated its ‘Outperform’ rating for ADCT, as published in its report on November 09, 2021. Jefferies’s report from August 17, 2021 suggests a price prediction of $40 for ADCT shares, giving the stock a ‘Buy’ rating. RBC Capital Mkts also rated the stock as ‘Outperform’.
Analysis of ADC Therapeutics SA (ADCT)
Further, the quarter-over-quarter increase in sales is 310.60%, showing a positive trend in the upcoming months.
ADC Therapeutics SA’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. The goal here is to ensure that your current return on equity of -132.20% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.30, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and ADCT is registering an average volume of 640.10K. On a monthly basis, the volatility of the stock is set at 8.31%, whereas on a weekly basis, it is put at 10.87%, with a gain of 3.54% over the past seven days. Furthermore, long-term investors anticipate a median target price of $12.17, showing growth from the present price of $2.05, which can serve as yet another indication of whether ADCT is worth investing in or should be passed over.
How Do You Analyze ADC Therapeutics SA Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 32.60%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 51.50% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in ADCT shares?
The recent increase in stakes in ADCT appears to be a result of several institutional investors and hedge funds increasing their positions. Redmile Group LLC’s position in ADCT has increased by 78.71% in the first quarter. The company now owns 13,565,249 shares of the stock, with a value of $48.83 million, following the purchase of 5,974,400 additional shares during the last quarter. Fidelity Management & Research Co made another decreased to its shares in ADCT during the first quarter, downing its stake by -39.79%. During the last quarter, the company picked up -2,970,611 additional shares for a total stake of worth $16.18 million, bringing number of shares owned by the company to 4,494,817.
During the first quarter, Millennium Management LLC added a 2,980,867 position in ADCT. AllianceBernstein LP sold an additional 90204.0 shares in the last quarter, decreasing its holdings by -3.09%, now holding 2.82 million shares worth $10.17 million. At the end of the first quarter, Goldman Sachs & Co. LLC increased its ADCT holdings by 7,442.68% and now holds 2.16 million ADCT shares valued at $7.78 million with the added 2.13 million shares during the period. ADCT shares are owned by institutional investors to the tune of 51.50% at present.
